Investor Relations

We are Anchiano Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need.

Our initial program is the genetic therapy for early stage bladder cancer. Inodiftagene visteplasmid (BC-819), our most advanced investigational agent, is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC).

We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Tel Aviv Stock Exchange.

Scientific and Medical

Focus on discovering and developing therapies for patients with cancer in areas of unmet need

Initial program: genetic therapy for early stage bladder cancer

Utilizes technology licensed from Hebrew University


Founded in 2004; based in Cambridge and Jerusalem

New CEO (former Harvard faculty; Ariad chief medical officer) based in Cambridge, building U.S. team and infrastructure


$33 million (end Q1 2018)
Approximate market capitalization

Publicly traded in Israel (TASE:ANCN)

96 million
outstanding shares

108 million
fully diluted

$0.6 million (end Q1 2018)
cash, no debt


Ashley Robinson, LifeSci Advisors


20th Annual Global Investment Conference 


Corporate Presentation